Search

This article discusses two cases of Darier disease, a chronic skin condition characterized by keratotic papules and other symptoms. The patients had previously tried various treatments with limited success. However, they showed significant improvement after being treated with apremilast, a medication approved for other skin conditions. The authors suggest that apremilast may help control inflammation and regulate calcium levels in Darier disease. Further studies are needed to confirm the efficacy of apremilast for this condition. [Extracted from the article]

Background/Objectives: To date, scientific data on the efficacy of botulinum toxin type A (BoNT‐A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT‐A for PPH on a large series of patients. Methods: Medical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT‐A for PPH from March 2003 until December 2022 were reviewed. Results: A total of 129 patients [12 males, 117 females; median age 32 years (range, 16–72)] were included in the study, after excluding 24 patients with insufficient documented follow‐up data. Most patients [115 (89.1%)] received onabotulinumtoxin‐A, nine (7.0%) abobotulinumtoxin‐A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported. Conclusions: The results of this retrospective study suggest that BoNT‐A is an effective and safe treatment option for PPH. [ABSTRACT FROM AUTHOR]

Background: Recent trends in the sensitization of construction workers show a decrease in potassium dichromate and an increase in epoxy resin sensitization. Objectives: To present the trends of occupational contact allergy of construction workers in Greece from 2009 to 2018. Methods: We retrospectively reviewed the files of patients with eczema patch tested in our Contact Dermatitis Clinic who were construction workers. Results: A total of 191 construction workers initially reported contact dermatitis. Of these, 138 had occupation‐relevant allergic contact dermatitis (ACD) or irritant contact dermatitis (ICD). All patients were men. After being patch tested, 98 (71.0%) were diagnosed with ACD and 40 with ICD. Median duration of occupation till onset of ACD was 2 years (interquartile range [IQR] 0.8–7). The hands were the most common location for ACD (73.5%), followed by the trunk (39.8%), the legs (38.8%), and the face (11.2%). Of the patients, 74.6% had lesions affecting multiple body sites. Potassium dichromate (67%) was the most frequent allergen, followed by thiuram mix (37.4%) and cobalt chloride (31.8%). Sensitization to epoxy resins was lower (12.1%). Conclusion: The sensitization pattern of Greek construction workers does not follow the trends in Central or Northern Europe, rather sharing attributes with less industrialized countries. [ABSTRACT FROM AUTHOR]

Abstract Introduction Pityriasis rubra pilaris is an uncommon inflammatory and hyperproliferative dermatosis of juvenile or adult onset. The etiology of the disease is still unknown. Case presentation We present the cases of two Caucasian men aged 53 and 48 who presented with pityriasis rubra pillaris type 1; both patients also exhibited an abnormal immunological profile. Conclusion Pityriasis rubra pillaris is currently classified as a keratinization disorder. The abnormal immunological profile reported in our patients along with the comorbidity of pityriasis rubra pilaris with autoimmune disorders reported in the literature poses the question of a possible pathogenetic role for the immune response in this disorder.

Several therapeutic approaches have been described for their treatment of hypertrophic scars and keloids, but to date, the optimal treatment has not been established yet. Our in vivo study was conducted to evaluate the effect of a medical device consisting in an adhesive patch containing onion extract (Allium cepa) 10%, allantoin 1%, and pentaglycan 4% (Kaloidon patch) on hypertrophic scars and keloids. Thirty‐nine patients with hypertrophic scars and seven patients with keloids were asked to apply an adhesive patch containing Allium cepa, allantoin, and pentaglycan once/day for at least 8 h consecutively, for 24 weeks. Patients were reevaluated 6 weeks (T6), 12 weeks (T12), and 24 weeks (T24) after starting the treatment through POSAS scale v 2.0, ultrasonographic, and videocapillaroscopic assessment. The investigated medical device was able to induce a significant improvement of POSAS starting from T12, with a positive amelioration trend until T24. However the patient‐assessed POSAS sub‐items showed improvement already after 6 weeks, whereas a significant improvement of the observer‐assessed POSAS sub‐items was observed only after 12 weeks (P <.001). Ultrasonography and intravital videocapillaroscopy confirmed a significant improvement of skin scars thickness (P <.001) and vascularization (P <.001) after 12 weeks of medical device application at least, with increasing improvement until T24. Applying an adhesive patch containing Allium cepa, allantoin, and pentaglycan once a day for at least 8 consecutive hours seems to be able to improve the clinical and morphological characteristics of the scars of the skin in 24 weeks. [ABSTRACT FROM AUTHOR]